Phase I/II placebo-controlled RCT in 166 healthy adults (150 aged 55-70): two doses of the Klebsiella pneumoniae O-antigen vaccine Kleb4V were well tolerated, with mostly mild-moderate AEs, and immunogenic for all four serotypes; O3b responses were weaker.
RCTn = 166
Alaimo et al. Safety and Immunogenicity of a Klebsiella pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A First-in-Human Phase I/II Randomized and Controlled Study